G Malietzis1, O Aziz2, N M Bagnall1, N Johns3, K C Fearon3, J T Jenkins4. 1. Department of Surgery, St. Mark's Hospital, Watford Road, Harrow, Middlesex HA1 3UJ, United Kingdom; Department of Surgery and Cancer, Imperial College, Paddington, London W2 1NY, United Kingdom. 2. Department of Colorectal Surgery, The Christie NHS Foundation Trust, Manchester M20 4BX, United Kingdom. 3. Department of Clinical and Surgical Sciences, University of Edinburgh, Edinburgh EH16 4SB, United Kingdom. 4. Department of Surgery, St. Mark's Hospital, Watford Road, Harrow, Middlesex HA1 3UJ, United Kingdom; Department of Surgery and Cancer, Imperial College, Paddington, London W2 1NY, United Kingdom. Electronic address: i.jenkins@nhs.net.
Abstract
BACKGROUND: Strong evidence indicates that excessive adipose tissue distribution or reduced muscle influence short-, mid-, and long-term colorectal cancer outcomes. Computerized tomography-based body composition (CTBC) analysis quantifies this in a reproducible parameter. We reviewed the evidence linking computerized tomography (CT) based quantification of BC with short and long-term outcomes in colorectal cancer (CRC). METHODS: A systematic review was performed according to PRISMA guidelines. A literature search was performed by two independent reviewers on all studies that included CTBC analysis in patients undergoing treatment for CRC using Medline, EMBASE, Google Scholar, and Cochrane databases. Outcomes of interest included short-term recovery, oncological outcomes, and survival. RESULTS: Seventy-five studies were identified; sixteen met the inclusion criteria. None were randomized controlled trials and all were cohort studies of small sample size. Several types of CTBC image analysis software were identified, reporting subcutaneous, visceral and skeletal muscle tissues. Visceral obesity and reduced muscle mass were categorical parameters quantified by CTBC analysis. Due to marked study heterogeneity, quantitative data synthesis was not possible. High visceral adipose tissue and reduced skeletal muscle resulted in poorer short-term recovery (eleven studies), poorer oncological outcomes (six studies), and poorer survival (six studies). CONCLUSIONS: CTBC techniques may be linked to outcomes in colorectal cancer patients, however larger studies are required. CTBC based assessment may allow early identification of high-risk patients, allowing early optimisation of patients undergoing cancer treatments.
BACKGROUND: Strong evidence indicates that excessive adipose tissue distribution or reduced muscle influence short-, mid-, and long-term colorectal cancer outcomes. Computerized tomography-based body composition (CTBC) analysis quantifies this in a reproducible parameter. We reviewed the evidence linking computerized tomography (CT) based quantification of BC with short and long-term outcomes in colorectal cancer (CRC). METHODS: A systematic review was performed according to PRISMA guidelines. A literature search was performed by two independent reviewers on all studies that included CTBC analysis in patients undergoing treatment for CRC using Medline, EMBASE, Google Scholar, and Cochrane databases. Outcomes of interest included short-term recovery, oncological outcomes, and survival. RESULTS: Seventy-five studies were identified; sixteen met the inclusion criteria. None were randomized controlled trials and all were cohort studies of small sample size. Several types of CTBC image analysis software were identified, reporting subcutaneous, visceral and skeletal muscle tissues. Visceral obesity and reduced muscle mass were categorical parameters quantified by CTBC analysis. Due to marked study heterogeneity, quantitative data synthesis was not possible. High visceral adipose tissue and reduced skeletal muscle resulted in poorer short-term recovery (eleven studies), poorer oncological outcomes (six studies), and poorer survival (six studies). CONCLUSIONS:CTBC techniques may be linked to outcomes in colorectal cancerpatients, however larger studies are required. CTBC based assessment may allow early identification of high-risk patients, allowing early optimisation of patients undergoing cancer treatments.
Authors: Jessica J Hopkins; Rebecca Reif; David Bigam; Vickie E Baracos; Dean T Eurich; Michael M Sawyer Journal: World J Surg Date: 2019-10 Impact factor: 3.352
Authors: Bette J Caan; Jeffrey A Meyerhardt; Candyce H Kroenke; Stacey Alexeeff; Jingjie Xiao; Erin Weltzien; Elizabeth Cespedes Feliciano; Adrienne L Castillo; Charles P Quesenberry; Marilyn L Kwan; Carla M Prado Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-05-15 Impact factor: 4.254
Authors: George Malietzis; Gui Han Lee; Hafid O Al-Hassi; David Bernardo; Alexandra I F Blakemore; Robin H Kennedy; Morgan Moorghen; John T Jenkins; Stella C Knight Journal: Tumour Biol Date: 2016-03-10
Authors: Stéphanie M L M Looijaard; Carel G M Meskers; Monique S Slee-Valentijn; Donald E Bouman; A N Machteld Wymenga; Joost M Klaase; Andrea B Maier Journal: Oncologist Date: 2019-11-20
Authors: Elizabeth M Cespedes Feliciano; Valerie S Lee; Carla M Prado; Jeffrey A Meyerhardt; Stacey Alexeeff; Candyce H Kroenke; Jingjie Xiao; Adrienne L Castillo; Bette J Caan Journal: Cancer Date: 2017-09-07 Impact factor: 6.860
Authors: Sarah A Purcell; Sarah A Elliott; Candyce H Kroenke; Michael B Sawyer; Carla M Prado Journal: Curr Oncol Rep Date: 2016-02 Impact factor: 5.075